資源描述:
《補(bǔ)腎調(diào)肝清心方對(duì)圍絕經(jīng)期抑郁癥睡眠障礙大鼠模型海馬5-羥色胺1A受體、5-羥色胺2A受體的影響.pdf》由會(huì)員上傳分享,免費(fèi)在線閱讀,更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫(kù)。
1、環(huán)球中醫(yī)藥2014年6月第7卷第6期GlobalTraditionalChineseMedicine,June2014,Vo1.7,Nn6411·論著·補(bǔ)腎調(diào)肝清心方對(duì)圍絕經(jīng)期抑郁癥睡眠障礙大鼠模型海馬5一羥色胺1A受體、5.羥色胺2A受體的影響何軍琴尹曉丹辛明蔚【摘要】目的觀察補(bǔ)腎調(diào)肝清心方對(duì)圍絕經(jīng)期抑郁癥睡眠障礙模型大鼠海馬5。羥色胺1A受體(5一hydr0xytryptamine1Areceptor,5-HT1AR)、5-羥色胺2A受體(5-hydroxytryptamine2Arecep—tor,5
2、-HT2AR)的影響。方法將60只圍絕經(jīng)期大鼠按體重隨機(jī)分為5組,每組12只:圍絕經(jīng)期正常對(duì)照組(A);圍絕經(jīng)期抑郁癥睡眠障礙模型組(B);圍絕經(jīng)期抑郁癥睡眠障礙補(bǔ)佳樂(lè)治療組(C);圍絕經(jīng)期抑郁癥睡眠障礙米氮平治療組(D);圍絕經(jīng)期抑郁癥睡眠障礙中藥治療組(E);A組為圍絕經(jīng)期正常大鼠,其余4組進(jìn)行18天不可預(yù)知慢性應(yīng)激。于應(yīng)激后對(duì)造模動(dòng)物進(jìn)行72小時(shí)連續(xù)快速眼相睡眠剝奪(REM)。每天在應(yīng)激前1小時(shí)按組給藥。在末次灌胃24小時(shí)后,頸椎脫臼法處死大鼠,取大鼠海馬,分別用熒光定量檢測(cè)海馬5-HT1ARmRNA
3、和5-HT2ARmRNA、蛋白印跡和免疫熒光檢測(cè)海馬5-HT1AR和5-HT2AR的表達(dá)。結(jié)果蛋白印跡檢測(cè)(westernblot)海馬及免疫熒光檢測(cè)海馬CA1區(qū)均顯示:海馬區(qū)5-HT1AR表達(dá)水平各組無(wú)明顯差異(P>0.05),而5-HT2AR表達(dá)水平上,模型組顯著低于正常組(P<0.05),治療組提高了5-HT2AR的表達(dá)水平,且與模型組相比存在顯著性差異(P<0.05);RT—PCR顯示:海馬區(qū)5-HT1ARmRNA水平各組無(wú)明顯差異(P>0.05),而5-HT2ARmRNA水平,模型組明顯低于正常組
4、(P<0.01),米氮平組較模型組有極顯著性差異(P<0.001),中藥組較模型組有顯著性差異(P<0.05)。結(jié)論補(bǔ)腎調(diào)肝清心方能提高5-HT2AR的mRNA及蛋白水平的表達(dá),免疫熒光的結(jié)果表明在海馬CA1區(qū)發(fā)揮作用,表明補(bǔ)腎調(diào)肝清心方可以通過(guò)調(diào)節(jié)海馬CA1區(qū)5-HT2AR表達(dá)來(lái)改善睡眠障礙。【關(guān)鍵詞】圍絕經(jīng)期抑郁癥睡眠障礙;補(bǔ)腎調(diào)肝清心方;5-羥色胺1A受體;5-羥色胺2A受體【中圖分類號(hào)】R285.5【文獻(xiàn)標(biāo)識(shí)碼】Adoi:10.3969/j.issn.1674—1749.2014.06.003Efe
5、ctofBushenTiaoganQingxindecoctiononhippocampal5-HT1Aand5-HT2Areceptorofperi·menopaus~depressionmodelratsHEJun—qin,YINXiao—dan,XINMing—wei.BengObstetricsandGynecologyHospital,CapitalUnive~ityofMedicalSciences,Bering100026,ChinaCorrespondingauthor:HEJun—qin,
6、E—mail:junqinhe@sina.tom【Abstract】ObjectiveObservetheeffectofBushenTiaoganQingxindecoctiononhippocampal5一HT1Aand5-HT2AreceptorofPerimenopausaldepressionmodelrats.Methods60perimenopausalratswererandomlydividedinto5groups,12ratsineachgroup.Thenormalgroup(A);
7、perimenopausalde—pressionsleepdisordermodelgroup(B);perimenopausaldepressionsleepdisorderprogynovatreatmentgroup(C);perimenopausaldepressionsleepdisordermirtazapinetreatmentgroup(D);perimenopausaldepressionsleepdisorderTCMtreatmentgroup(E).Agroupisperimeno
8、pausalnormalrats,theother4groupswereunder18daysofunpredictablechronicstress.Afterthelastadministration,theratswerekill—edbycervicaldislocationtogetthehippocampusandtestthe5-HT1AreceptormRNAand5-HT2Arecep—torm